Maprotiline HClNoradrenalin re-uptake inhibitor CAS# 10347-81-6 |
2D Structure
- Laminin (925-933)
Catalog No.:BCC1015
CAS No.:110590-60-8
- Epidermal Growth Factor Receptor Peptide (985-996)
Catalog No.:BCC1014
CAS No.:96249-43-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 10347-81-6 | SDF | Download SDF |
PubChem ID | 71478 | Appearance | Powder |
Formula | C20H24ClN | M.Wt | 313.86 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 37 mg/mL (117.89 mM) *"≥" means soluble, but saturation unknown. | ||
SMILES | CNCCCC12CCC(C3=CC=CC=C31)C4=CC=CC=C24.Cl | ||
Standard InChIKey | NZDMFGKECODQRY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C20H23N.ClH/c1-21-14-6-12-20-13-11-15(16-7-2-4-9-18(16)20)17-8-3-5-10-19(17)20;/h2-5,7-10,15,21H,6,11-14H2,1H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective noradrenalin re-uptake inhibitor. |
Maprotiline HCl Dilution Calculator
Maprotiline HCl Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1861 mL | 15.9307 mL | 31.8613 mL | 63.7227 mL | 79.6533 mL |
5 mM | 0.6372 mL | 3.1861 mL | 6.3723 mL | 12.7445 mL | 15.9307 mL |
10 mM | 0.3186 mL | 1.5931 mL | 3.1861 mL | 6.3723 mL | 7.9653 mL |
50 mM | 0.0637 mL | 0.3186 mL | 0.6372 mL | 1.2745 mL | 1.5931 mL |
100 mM | 0.0319 mL | 0.1593 mL | 0.3186 mL | 0.6372 mL | 0.7965 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Maprotiline HCl
- NMS-1286937
Catalog No.:BCC5358
CAS No.:1034616-18-6
- Xanthone V1a
Catalog No.:BCN7922
CAS No.:103450-96-0
- Z-Cyclopentyl-AP4
Catalog No.:BCC7616
CAS No.:103439-17-4
- CTAP
Catalog No.:BCC5776
CAS No.:103429-32-9
- CTOP
Catalog No.:BCC5780
CAS No.:103429-31-8
- Devazepide
Catalog No.:BCC7319
CAS No.:103420-77-5
- Disodium (R)-2-Hydroxyglutarate
Catalog No.:BCC6515
CAS No.:103404-90-6
- Octyl gallate
Catalog No.:BCN8432
CAS No.:1034-01-1
- 1-O-Methylnataloe-emodin
Catalog No.:BCN7036
CAS No.:103392-51-4
- HPGDS inhibitor 1
Catalog No.:BCC4065
CAS No.:1033836-12-2
- Telotristat
Catalog No.:BCC5128
CAS No.:1033805-28-5
- Salidroside
Catalog No.:BCN5966
CAS No.:10338-51-9
- Leupeptin, Microbial
Catalog No.:BCC1217
CAS No.:103476-89-7
- Diacetylpiptocarphol
Catalog No.:BCN4737
CAS No.:103476-99-9
- Fmoc-D-N- Me-Val-OH
Catalog No.:BCC3359
CAS No.:103478-58-6
- Fmoc-N-Me-Leu-OH
Catalog No.:BCC3345
CAS No.:103478-62-2
- Fmoc-D-N-Me-Leu-OH
Catalog No.:BCC3346
CAS No.:103478-63-3
- 9-Dehydroandrostenedione
Catalog No.:BCC8801
CAS No.:1035-69-4
- Phyllanthin
Catalog No.:BCN5848
CAS No.:10351-88-9
- AZ505
Catalog No.:BCC4264
CAS No.:1035227-43-0
- AZ505 ditrifluoroacetate
Catalog No.:BCC4265
CAS No.:1035227-44-1
- AZD4547
Catalog No.:BCC3711
CAS No.:1035270-39-3
- Apiosylskimmin
Catalog No.:BCN2455
CAS No.:103529-94-8
- Huperzine B
Catalog No.:BCN1059
CAS No.:103548-82-9
Convulsive attacks due to antidepressant drug overdoses: case reports and discussion.[Pubmed:6138296]
Gen Hosp Psychiatry. 1983 Sep;5(3):217-21.
Antidepressant drug overdoses have been reported to induce seizures, but the etiology of this phenomenon is still unclear. Recently we treated three patients who suffered from epileptic seizures after acute overdoses of three antidepressant drugs: (a) Dibenzepin HCl (Noveril), (b) Maprotiline HCl (Ludiomil), and (c) Clorimipramine (Anafranil). After a review of the pertinent literature, the possible role of antidepressant drugs in the genesis of epileptic seizures is discussed.
Behavioural effects in mice of subchronic chlordiazepoxide, maprotiline and fluvoxamine. II. The elevated plus-maze.[Pubmed:9164563]
Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):127-36.
In view of apparent commonalities in the aetiology, symptomatology, and pharmacotherapy of anxiety and depressive disorders, the present study compares the effects of the benzodiazepine, chlordiazepoxide (1.0-8.0 mg/kg), the selective noradrenaline (NA) reuptake inhibitor, maprotiline (0.5-10.0 mg/kg), and the serotonin (5-HT)-selective reuptake inhibitor, fluvoxamine (2.0-8.0 mg/kg), on the behaviour of mice in the elevated plus-maze test of anxiety. To more accurately reflect the clinical situation, subjects were treated daily for 21 days prior to testing, and comprehensive behavioural profiles were obtained through the application of an ethological scoring technique. Results show that subchronic treatment with chlordiazepoxide produced clear anxiolytic-like effects at the highest dose tested, coupled with an inhibition of risk assessment over the entire dose range. With the exception of risk assessment measures, anxiolytic-like effects were also seen with a low dose (0.5 mg/kg) of maprotiline: these effects were lost at higher doses. In contrast to these data, fluvoxamine produced minimal behavioural change under present test conditions. Findings are discussed in relation to the relative efficacy of selective monoamine. reuptake inhibitors in the treatment of anxiety disorders, and the nature of anxiety evoked in mice by exposure to the elevated plus-maze.
Biochemical and pharmacological tests for the prediction of ability of monoamine uptake blockers to inhibit the uptake of noradrenaline in-vivo: the effects of desipramine, maprotiline, femoxetine and citalopram.[Pubmed:2894425]
J Pharm Pharmacol. 1987 Dec;39(12):1003-9.
The ability of desipramine and maprotiline (NA uptake inhibitors), as well as citalopram and femoxetine (5-HT uptake inhibitors) to protect mice against brain NA depletion induced by H 77/77 (4-alpha-dimethyl-m-tyramine), has been compared with their ability to counteract reserpine (2.5 mg kg-1)- or apomorphine (16 mg kg-1)-induced hypothermia and to potentiate TRH (40 mg kg-1)-induced hyperthermia in mice. While both NA uptake inhibitors antagonized the action of H 77/77, maprotiline being weaker than desipramine, femoxetine and citalopram were inactive. However, in contrast to citalopram, femoxetine was active in the other tests, being about twice as weak as maprotiline, which itself was several times weaker than desipramine in those tests. On the basis of the results obtained it is concluded that functional in-vivo tests for NA uptake inhibitors are more sensitive than the H 77/77 biochemical test; moreover, femoxetine, which in-vitro studies is less selective than citalopram, may inhibit the uptake of NA in-vivo.